Why investors praise research spending in theory but punish it in practice

Investors often demand that companies spend more money on research and development and new capacity building, but react with worry when firms actually make those investments. An investor named Bertie recently attended a Wall Street bank meeting where a global macro economist displayed charts showing India's low spending on research and development and private-sector capital expenditure. The presentation featured comparisons with other countries and advice that India needed to invest more in innovative research and build capacity.

Corporate Realities

Later in the week, Bertie met the leaders of two pharmaceutical companies working on innovative research. Both firms had spent millions of dollars over the years to discover and sell new medicines. Capital markets had been deeply sceptical of these ambitions, giving the companies poor valuations and forcing them to sell existing profitable businesses and brands to keep research going. When one chief executive officer said he planned to redouble research efforts after achieving early success, the mood in the room turned heavy, with questions quickly shifting to free cash flow generation, debt ratios, and return on equity.

Auto Ancillary Pivot

Towards the end of the week, Bertie met a small auto ancillary company whose products faced the risk of becoming obsolete as vehicle sales shifted from internal combustion engines to electric vehicles. The company had previously distributed a large surplus cash balance to shareholders, earning an attractive dividend yield. The chief executive outlined a plan to enter the electric battery business by investing as much over the next three years as it had over the previous fifty. This major shift meant dividends would have to be cut and could even drop to zero. Investors responded by advising the chief executive to take a calibrated approach to fresh investments while keeping the company's fundamental attractiveness intact.

Context

Macroeconomic charts highlighting low research spending and weak capital expenditure are built from thousands of individual decisions made by companies, households, and governments. Investors frequently call for broader national progress in innovation, yet individual shareholders often penalise specific companies that sacrifice short-term cash flows and dividends to fund those very long-term goals.